AXSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Axsome Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$155.81−1.33 (-0.85%)
Close on Oct 19, 2026
- Market cap
- $8.07B
- P/E (TTM)
- –
- Dividend yield
- –
Axsome Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Axsome Therapeutics | Industry median |
|---|---|---|
| Market Cap | $8.16B | $166.30M |
| Enterprise Value | $8.03B | $87.12M |
| PS Ratio | 10.51 | 3.60 |
| PB Ratio | 97.97 | 2.03 |
| P/TBV Ratio | 240.72 | 2.31 |
Enterprise value
| Measure | Axsome Therapeutics | Industry median |
|---|---|---|
| EV / Sales | 10.34 | 2.43 |
Income (trailing twelve months)
| Measure | Axsome Therapeutics | Industry median |
|---|---|---|
| Revenue | $776.57M | $57.94M |
| Gross Profit | $724.04M | $90.47M |
| Operating Income | -$186.07M | -$21.49M |
| Pretax Income | -$191.09M | -$14.72M |
| Net Income | -$191.64M | -$22.46M |
| EBITDA | -$186.07M | -$17.14M |
| EPS (Diluted) | -$3.75 | -$0.83 |
Margins
| Measure | Axsome Therapeutics | Industry median |
|---|---|---|
| Gross Margin | 93.2% | 52.3% |
| Operating Margin | -24.0% | -44.5% |
| Pretax Margin | -24.6% | -13.0% |
| Profit Margin | -24.7% | -39.2% |
| EBITDA Margin | -24.0% | -31.3% |
| FCF Margin | -9.27% | -8.85% |
Returns
| Measure | Axsome Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -245.1% | -53.2% |
| Return on Assets (ROA) | -27.4% | -41.0% |
| Return on Capital Employed (ROCE) | -61.8% | -38.0% |
Growth
| Measure | Axsome Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 56.9% | 6.01% |
| Revenue Growth (3Y CAGR) | 133.7% | 2.25% |
Balance sheet
| Measure | Axsome Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $319.85M | $62.64M |
| Total Debt | $187.96M | $120.13M |
| Net Cash (Debt) | $131.89M | $15.77M |
| Net Cash Per Share | $2.52 | $0.66 |
| Equity (Book Value) | $83.30M | $48.61M |
| Book Value Per Share | $1.59 | $1.36 |
| Tangible Book Value | $33.90M | $23.01M |
| Working Capital | $196.12M | $75.09M |
Financial position
| Measure | Axsome Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 1.43 | 3.30 |
| Quick Ratio | 1.30 | 2.39 |
| Debt / Equity | 2.26 | 0.51 |
Cash flow (trailing twelve months)
| Measure | Axsome Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$71.26M | -$12.39M |
| Capital Expenditures | -$700.00K | -$1.07M |
| Free Cash Flow | -$71.96M | -$20.34M |
| FCF Per Share | -$1.37 | -$0.42 |
Efficiency
| Measure | Axsome Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 1.11 | 0.38 |
| Inventory Turnover | 1.87 | 2.67 |
| Revenue Per Employee | $1.55M | $398.96K |
| Profits Per Employee | -$383.29K | -$705.27K |
| Employee Count | 500 | 74 |
Dividends and yields
| Measure | Axsome Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -2.35% | -22.8% |
| FCF Yield | -0.88% | -9.02% |
| Buyback Yield | -0.43% | -0.73% |
| Shareholder Yield | -0.43% | 0.00% |
Shares
| Measure | Axsome Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 52,380,800 | 58,139,000 |
| Shares Change (YoY) | 4.44% | 11.1% |
| Shares Change (QoQ) | 1.71% | 0.54% |
| Float | 44,405,500 | 49,154,900 |
| Shares Held by Insiders | 15.2% | 11.6% |
| Shares Held by Institutions | 73.8% | 59.4% |
Taxes
| Measure | Axsome Therapeutics | Industry median |
|---|---|---|
| Income Tax | $558.00K | $89.00K |
Scores
| Measure | Axsome Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 5.13 | -0.27 |
| Piotroski F-Score | 5 | 4 |
Calculated by StockData from Axsome Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.